Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient between the ages of 25 and 70 years old~2. Male patient, in the case of female patient, postmenopausal women, or women physically incapable of childbearing~3. Subject who underwent surgery specially for the clinical study~4. Ability to provide written informed consent prior to any study procedures.~5. Ability to understand study procedures and communicate clearly with the investigator and staff.~6. Subjects with body weight under 100kg and body mass index (BMI) level lower than 35 kg/m2, inclusive~Exclusion Criteria:~\< Surgical Factors \>~1. Emergency or unplanned surgery.~2. Repeat operation (e.g., previous surgery within 30 days for same condition).~3. Cancer-related condition causing preoperative pain in site of surgery.~   \< Subject Characteristics \>~4. Women with childbearing potential, Women who are pregnant or breastfeeding.~5. Chronic pain diagnosis (e.g., ongoing pain at baseline with NRS ≥ 4/10).~6. Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, anxiety, or depression). Subjects who take stable doses (same dose \>30 days) of antidepressants and anti-anxiety drugs may be included.~7. Unstable or acute medical condition (e.g., unstable angina, congestive heart failure, renal failure, hepatic failure, AIDS).~8. Subjects who have long PR (\>200msec) or prolonged QTc (\> 450msec in male, \>470msec in female) at Screening~   \< Drug, Alcohol, and Pharmacological Considerations \>~9. History of alcohol, opiate or other drug abuse or dependence within 12 months prior to Screening .~10. Ongoing or recent (within 30 days prior to surgery) use of steroids, opioids, or antipsychotics.~11. Alcohol consumption within 24 hours of surgery.~12. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen within 24 hours of surgery.~13. Use of herbal agents or nutraceuticals (i.e., chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) within 7 days prior to surgery.~    \< Anesthetic and Other Exclusion Considerations \>~14. Use of neuraxial or regional anesthesia related to the surgery.~15. Use of ketamine, gabapentin, pregabalin, or lidocaine (\>1 mg/kg) intra or peri-operatively, or within 24 hours of surgery.~16. Subject with known allergies to hydromorphone.~17. Subjects who received another investigational drug within 30 days of scheduled surgery

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- VVZ-149 injection (Type: EXPERIMENTAL): VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 9.5 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group will receive an water for injection the same volume and period of experimental group.

Based on this trial design, predict the completion outcome and termination type (if applicable).